Pharmacokinetics of Once-Daily Boosted Elvitegravir When Administered in Combination With Acid-Reducing Agents

被引:0
作者
Ramanathan, Srinivasan [1 ]
Mathias, Anita [1 ]
Wei, Xuelian [1 ]
Shen, Gong [1 ]
Koziara, Joanna [1 ]
Cheng, Andrew [1 ]
Kearney, Brian P. [1 ]
机构
[1] Gilead Sci Inc, Clin Res, Foster City, CA 94404 USA
关键词
elvitegravir; acid-reducing agent; antacid; omeprazole; famotidine; CO-FORMULATED ELVITEGRAVIR; DISOPROXIL FUMARATE; INITIAL TREATMENT; HIV-1; INFECTION; DOUBLE-BLIND; INTEGRASE; RITONAVIR; EMTRICITABINE; OMEPRAZOLE; TENOFOVIR;
D O I
暂无
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Acid-reducing agents are commonly used co-medications by HIV-1-infected patients receiving antiretroviral treatment. The effects of various representative acid-reducing agents on the pharmacokinetics (PK) of boosted elvitegravir were evaluated by 1-way interaction in 4 studies. Methods: Healthy subjects received ritonavir-boosted elvitegravir (EVG/r; 50/100 mg QD) administered alone or with antacid simultaneously in Study 1, staggered (+/- 2 or +/- 4 hours) or with omeprazole in Study 2; Studies 3 and 4 evaluated cobicistat-boosted elvitegravir (EVG/co; 150/150 mg QD) administered simultaneously or staggered (+ 12 hours) with famotidine or omeprazole. Lack of PK alteration was defined as 90% confidence intervals about the geometric least squares means ratio (coadministration: alone) being within 70%-143% for elvitegravir C-max (maximum concentration), C-tau (trough), and AUC(tau) (area under plasma concentration-time curve; 0-24 hours); cobicistat PK were explored. Results: EVG exposures were 40%-50% lower upon simultaneous dosing of EVG/r and antacids, probably due to local complexation with cations in gastrointestinal tract, and were unaffected with >= 2 hours staggered dosing. No relevant drug interactions were observed between EVG/co and famotidine or between EVG/r or EVG/co and omeprazole, indicating the absence of a broader pH effect on boosted EVG PK. In all studies, study treatments were well tolerated, with adverse events being generally mild to moderate in severity and primarily gastrointestinal disorders. Conclusions: There are no clinically relevant interactions between boosted elvitegravir, and thus elvitegravir/cobicistat/emtricitabine/ tenofovir DF single-tablet regimen, and H2-receptor antagonists or proton pump inhibitors; staggered antacid administration by >= 2 hours is recommended.
引用
收藏
页码:45 / 50
页数:6
相关论文
共 21 条
[1]   Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients [J].
DeJesus, Edwin ;
Berger, Daniel ;
Markowitz, Martin ;
Cohen, Calvin ;
Hawkins, Trevor ;
Ruane, Peter ;
Elion, Richard ;
Farthing, Charles ;
Zhong, Lijie ;
Cheng, Andrew K. ;
McColl, Dainian ;
Kearney, Brian P. .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2006, 43 (01) :1-5
[2]   Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial [J].
DeJesus, Edwin ;
Rockstroh, Juergen K. ;
Henry, Keith ;
Molina, Jean-Michel ;
Gathe, Joseph ;
Ramanathan, Srinivasan ;
Wei, Xuelian ;
Yale, Kitty ;
Szwarcberg, Javier ;
White, Kirsten ;
Cheng, Andrew K. ;
Kearney, Brian P. .
LANCET, 2012, 379 (9835) :2429-2438
[3]   Pharmacokinetics and Bioavailability of an Integrase and Novel Pharmacoenhancer-Containing Single-Tablet Fixed-Dose Combination Regimen for the Treatment of HIV [J].
German, Polina ;
Warren, David ;
West, Steve ;
Hui, James ;
Kearney, Brian P. .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2010, 55 (03) :323-329
[4]   Effects of Omeprazole on Plasma Levels of Raltegravir [J].
Iwamoto, Marian ;
Wenning, Larissa A. ;
Nguyen, Bach-Yen ;
Teppler, Hedy ;
Moreau, Allison R. ;
Rhodes, Rand R. ;
Hanley, William D. ;
Jin, Bo ;
Harvey, Charlotte M. ;
Breidinger, Sheila A. ;
Azrolan, Neal ;
Farmer, H. Frank, Jr. ;
Isaacs, Robin D. ;
Chodakewitz, Jeffery A. ;
Stone, Julie A. ;
Wagner, John A. .
CLINICAL INFECTIOUS DISEASES, 2009, 48 (04) :489-492
[5]   Effect of Antacids on the Pharmacokinetics of Raltegravir in Human Immunodeficiency Virus-Seronegative Volunteers [J].
Kiser, Jennifer J. ;
Bumpass, J. Brock ;
Meditz, Amie L. ;
Anderson, Peter L. ;
Bushman, Lane ;
Ray, Michelle ;
Predhomme, Julie A. ;
Rower, Joseph ;
MaWhinney, Sam ;
Brundage, Richard .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (12) :4999-5003
[6]   Effects of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and ritonavir-boosted atazanavir [J].
Klein, Cheri E. ;
Chiu, Yi-Lin ;
Cai, Yan ;
Beck, Katrin ;
King, Kathryn R. ;
Causemaker, Sonja J. ;
Doan, Thao ;
Esslinger, Hans-Ulrich ;
Podsadecki, Thomas J. ;
Hanna, George J. .
JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (05) :553-562
[7]  
Luber A, 2004, HIV7 NOV 14 18 GLASG
[8]   Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers [J].
Luber, A. D. ;
Brower, R. ;
Kim, D. ;
Silverman, R. ;
Peloquin, C. A. ;
Frank, I. .
HIV MEDICINE, 2007, 8 (07) :457-464
[9]   Pharmacokinetics and Pharmacodynamics of GS-9350: A Novel Pharmacokinetic Enhancer Without Anti-HIV Activity [J].
Mathias, A. A. ;
German, P. ;
Murray, B. P. ;
Wei, L. ;
Jain, A. ;
West, S. ;
Warren, D. ;
Hui, J. ;
Kearney, B. P. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 (03) :322-329
[10]  
Mathias A LH, 2010, 11 INT WORKSH CLIN P